Daojun Mo

775 total citations
20 papers, 573 citations indexed

About

Daojun Mo is a scholar working on Rheumatology, Endocrinology, Diabetes and Metabolism and Hematology. According to data from OpenAlex, Daojun Mo has authored 20 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 9 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Hematology. Recurrent topics in Daojun Mo's work include Rheumatoid Arthritis Research and Therapies (8 papers), Growth Hormone and Insulin-like Growth Factors (7 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Daojun Mo is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (8 papers), Growth Hormone and Insulin-like Growth Factors (7 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Daojun Mo collaborates with scholars based in United States, Germany and Spain. Daojun Mo's co-authors include Andrea Attanasio, Jay Bae, Byron J. Hoogwerf, Maureen J. Lage, David R. Nelson, Eva Marie Erfurth, Philippe Chanson, Шломо Мелмед, Alan G. Zimmermann and Susan M. Webb and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

Daojun Mo

19 papers receiving 558 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daojun Mo United States	12	418	92	78	71	66	20	573
Ömer Tarım Türkiye	14	386 0.9×	39 0.4×	33 0.4×	99 1.4×	95 1.4×	55	832
Thomas Bo Jensen Denmark	15	107 0.3×	166 1.8×	30 0.4×	57 0.8×	27 0.4×	40	603
T J Hendra United Kingdom	11	223 0.5×	127 1.4×	21 0.3×	24 0.3×	31 0.5×	23	483
Joel Steelman United States	8	146 0.3×	16 0.2×	53 0.7×	65 0.9×	64 1.0×	14	398
Hernando Vargas‐Uricoechea Colombia	13	349 0.8×	71 0.8×	21 0.3×	17 0.2×	31 0.5×	52	568
Zohreh Karamizadeh Iran	12	106 0.3×	24 0.3×	56 0.7×	85 1.2×	16 0.2×	40	349
Ruth M. Belin United States	9	426 1.0×	25 0.3×	24 0.3×	52 0.7×	45 0.7×	15	744
Ola Ghatnekar Sweden	13	107 0.3×	86 0.9×	23 0.3×	22 0.3×	28 0.4×	23	528
Saleh Aldasouqi United States	12	203 0.5×	23 0.3×	19 0.2×	42 0.6×	47 0.7×	43	440

Countries citing papers authored by Daojun Mo

Since Specialization

Citations

This map shows the geographic impact of Daojun Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daojun Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daojun Mo more than expected).

Fields of papers citing papers by Daojun Mo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daojun Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daojun Mo. The network helps show where Daojun Mo may publish in the future.

Co-authorship network of co-authors of Daojun Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Daojun Mo. A scholar is included among the top collaborators of Daojun Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daojun Mo. Daojun Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Edwards, Christopher, Gerhard Krönke, Jérôme Avouac, et al.. (2025). Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study. The Journal of Rheumatology. 52(4). jrheum.2024–906. 1 indexed citations

Taylor, Peter C., Daniel Aletaha, Raimón Sanmartí, et al.. (2024). Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study. Lara D. Veeken. 63(10). 2799–2809. 4 indexed citations

Landewé, Robert, et al.. (2023). Robust analyses for radiographic progression in rheumatoid arthritis. RMD Open. 9(2). e002543–e002543.

Heijde, Désirée van der, Li Xie, Scott D. Beattie, et al.. (2021). Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. The Journal of Rheumatology. 49(2). 133–141. 7 indexed citations

Pope, Janet, Yvonne Lee, Jeffrey R. Curtis, et al.. (2021). Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib. ACR Open Rheumatology. 4(3). 254–258. 3 indexed citations

Winthrop, Kevin, Tsutomu Takeuchi, Gerd R Burmester, et al.. (2021). O09 Safety profile of baricitinib for the treatment of RA up to 8.4 years: an updated integrated safety analysis. Lara D. Veeken. 60(Supplement_1). 1 indexed citations

Genovese, Mark C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2020). Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. The Lancet Rheumatology. 2(6). e347–e357. 55 indexed citations

Genovese, Mark C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2019). THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 78. 308–309. 21 indexed citations

Bae, Jay, Maureen J. Lage, Daojun Mo, David R. Nelson, & Byron J. Hoogwerf. (2015). Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009–2011. Journal of Diabetes and its Complications. 30(2). 212–220. 102 indexed citations

10.

Mo, Daojun, Maria Fleseriu, Rong Qi, et al.. (2015). Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. The Lancet Diabetes & Endocrinology. 3(5). 331–338. 41 indexed citations

11.

Mo, Daojun, Werner Blum, Myriam Rosilio, et al.. (2014). Ten-Year Change in Quality of Life in Adults on Growth Hormone Replacement for Growth Hormone Deficiency: An Analysis of the Hypopituitary Control and Complications Study. The Journal of Clinical Endocrinology & Metabolism. 99(12). 4581–4588. 34 indexed citations

12.

Mo, Daojun, Dana S. Hardin, Eva Marie Erfurth, & Шломо Мелмед. (2013). Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS). Pituitary. 17(5). 477–485. 29 indexed citations

13.

Attanasio, Andrea, Heike Jung, Daojun Mo, et al.. (2011). Prevalence and Incidence of Diabetes Mellitus in Adult Patients on Growth Hormone Replacement for Growth Hormone Deficiency: A Surveillance Database Analysis. The Journal of Clinical Endocrinology & Metabolism. 96(7). 2255–2261. 52 indexed citations

14.

Webb, Susan M., Daojun Mo, Steven W. J. Lamberts, et al.. (2009). Metabolic, Cardiovascular, and Cerebrovascular Outcomes in Growth Hormone-Deficient Subjects with Previous Cushing’s Disease or Non-Functioning Pituitary Adenoma. The Journal of Clinical Endocrinology & Metabolism. 95(2). 630–638. 51 indexed citations

15.

Attanasio, Andrea, Daojun Mo, Eva Marie Erfurth, et al.. (2009). Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement. The Journal of Clinical Endocrinology & Metabolism. 95(1). 74–81. 93 indexed citations

16.

Webb, Susan M., Christian J. Strasburger, Daojun Mo, et al.. (2008). Changing Patterns of the Adult Growth Hormone Deficiency Diagnosis Documented in a Decade-Long Global Surveillance Database. The Journal of Clinical Endocrinology & Metabolism. 94(2). 392–399. 42 indexed citations

17.

Mo, Daojun, Xia Li, & Alan G. Zimmermann. (2008). Using Direct Standardization SAS® Macro for a Valid Comparison in Observational Studies. 1 indexed citations

18.

Rajmil, Luís, et al.. (2006). Preferencia de Tadalafilo vs Sildenafilo en pacientes españoles con disfunción eréctil: resultados procedentes de un estudio multicéntrico internacional. Actas Urológicas Españolas. 30(1). 67–79. 8 indexed citations

19.

Kloner, Robert A., et al.. (2005). Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. International Journal of Impotence Research. 17(5). 450–454. 16 indexed citations

20.

Veugelers, Paul J., A.M. Yip, & Daojun Mo. (2001). The North-South Gradient in Health: Analytic Applications for Public Health. Canadian Journal of Public Health. 92(2). 95–98. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact